CASP1 and acute myeloid leukemia: Orally active Caspase 1 inhibitor such as VX-765 [85] and other caspase 1 inhibitors such as soluble analogs of Parthenolide (anti-inflammatory sesquiterpene lactone compound) can also be potential drug targets in hematological lineage bias disorders such as MDS and AML, which have only been studied in epilepsy and dermatologic conditions so far.